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Chronic obstructive pulmonary disease
Coronary artery disease
Heart failure
Cardiovascular diseases are major public health problems. ß-
blockers therapy is indicated for the majority of patients with heart
failure and coronary artery disease (Class I, Level of Evidence: A).
These drugs are also ﬁrst-line therapy for atrial ﬁbrillation. However,
ß-blocker use continues to be less than optimal, principally in patients
with concomitant chronic obstructive lung diseases, such as asthma
and chronic obstructive pulmonary disease (COPD).
Historically, studies suggested that ß-blockers increased airway
hyperresponsiveness and competed with ß2-agonists, thus theoretical-
ly increasing the risk of adverse pulmonary outcomes. Cardioselective
ß-blockers have been designed to target ß1-adrenoreceptors (AR)
while avoiding ß2AR in the lung and elsewhere. However, these so
called cardioselective ß-blockers are only relatively selective and exert
signiﬁcantß2 antagonismat therapeutic doses, though to a lesser extent
than non-selective ß-blockers. Thus, it might seem counterintuitive to
prescribe both ß-blockers and ß-agonists in the same patient, even
when they are targeting different organs. As a result, ß-blockers are
often withheld or discontinued from patients with asthma or COPD,
especially in the setting of acute exacerbations.
Despite these concerns, evidence supports that chronic use of
cardioselective ß-blockers do not cause an increase of exacerbations, re-
duction in airway function or worsening of quality of life in patients
with cardiovascular and obstructive pulmonary diseases.
A meta-analysis of randomized controlled trials evaluating acute ß-
blocker exposure in asthma showed that selective ß-blockers caused a
mean reduction in forced expiratory volume in one second (FEV1) of
−6.9% (95% conﬁdence interval (CI),−8.5 to−5.2) [1]. However, this
change in FEV1 did not translate into symptoms. A dose–response
relationship was demonstrated for atenolol, bisoprolol and metoprolol.
Additionally, subgroup analysis suggested heterogeneity in treatment
effect of different selective ß-blockers, as celiprolol did not cause statis-
tically signiﬁcant changes in FEV1 [1].
Another systematic review of 22 randomized trials to evaluate the
effects of cardioselective ß-blockers in patients with COPD showed no
signiﬁcant change in respiratory symptoms or spirometry parameters,
when these drugs were given in a single dose or for a longer duration☆ The authors declare no conﬂicts of interest related to this study.
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response to ß2-agonist treatment. Subgroup analyses revealed no
signiﬁcant change in results for those participants with severe airways
obstruction or those with concomitant cardiovascular disease. These
authors also broadly analysed the effect of cardioselective ß–blockers
on respiratory function of patients with asthma or COPD with a revers-
ible obstructive component [3]. Although the ﬁrst dose of a ß-blocker
produced a small decrease in FEV1 (−7.5%, 95% CI−9.3 to−5.6), this
was not associatedwith an increase in symptoms. Importantly, continu-
ing therapy from three days to four weeks produced no signiﬁcant
change in FEV1, symptoms or inhaler use, compared to placebo.
It is interesting to note that a signiﬁcant improvement in the
response to inhaled salbutamol was seen with ß-blocker treatment,
suggesting an increased effect of ß2-agonist stimulation [3]. More
recently, after encouraging results in murine studies, the ﬁrst proof-of-
concept open-label study in humans was set to evaluate the safety
and effect of ß-blockers for the potential treatment of asthma. It showed
that chronic dose-escalating non-selective ß-blocker nadolol use in pa-
tients with steroid-naive mild asthma was not only safe but could have
beneﬁcial effects on airway hyperresponsiveness [4]. Indeed, in eight
out of the ten subjects evaluated, nine weeks of beta-blocker treatment
produced a signiﬁcant, dose-dependent increase in the methacholine
PC20. Moreover, a large retrospective cohort study suggested that
besides beingwell tolerated by patientswith COPD, ß-blockers could re-
duce the risk of exacerbations andmortality, when added to established
inhaled stepwise therapy, independent of overt cardiovascular disease
and cardiac drugs [5]. No signiﬁcant adverse effects on pulmonary
functionwere observed. A recentmeta-analysis of observational studies
supported these results [6]. Taken together, these observations suggest
that ß-blockers may have independent beneﬁcial effects in obstructive
lung diseases. One possibility is that up-regulation of ß2AR by chronic
ß-blockade may improve the effectiveness of ß2-agonists [5,7]. In this
regard, no adverse effect was observed with the addition of ß-blockers
to treatment regimens that included long-acting ß-agonists [5]. More-
over, co-administration of long-acting anti-muscarinic drugs may be
beneﬁcial to prevent ß-blocker induced bronchoconstriction. This
would suggest a rationale for using tiotropium when prescribing a ß-
blocker for a patient with obstructive pulmonary disease [5,7].
After these studies, the effect of chronic nonselective ß-blockagewas
assessed as add-on to inhaled corticosteroids in patients with stable
persistent asthma [8]. The authors reported no signiﬁcant effect of
propranolol compared with placebo on airway hyperreactivity, with
no signiﬁcant change in asthma control or quality of life but only partial
attenuation of acute salbutamol recovery after challenge. These at ﬁrst
sight discouraging results raised noteworthy discussion regarding the
importance of ß-blockers differential pharmacodynamics and ß2AR sig-
nalling in asthma [9]. The ß2AR signals via at least two independent
pathways: the G protein cyclic adenosine monophosphate (Gs-cAMP)
pathway, and the ß-arrestin and/or extracellular signal-regulated
kinases (ERK) activation. The endogenous ligand for the ß2AR, epineph-
rine, and ß2AR agonists used in asthma or COPD therapy, like salmeterolhts reserved.
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mechanisms mediating the efﬁcacy of ß-blockers point to differential
“ligand bias”, i.e., the ligand ability to selectively promote speciﬁc intra-
cellular signalling events [9,10]. Several in vitro and in vivo studies sug-
gest that ß-arrestin/ERK signalling is detrimental in asthma [9,10]. In
this regard, propranolol, similar to carvedilol, activates ß-arrestin/ERK
signalling, while shutting down the Gs-cAMP pathway, while nadolol
does the opposite. Thus, generalization of studies results simply regard-
ing ß-blockers as a “class” is not possible.
Ongoing basic and clinical research, including clinical trials regard-
ing speciﬁc ß-blockers will add compelling data to our knowledge on
these drugs effects in obstructive pulmonary diseases. While data
supporting longer-term safety is still lacking for patients with concom-
itant pulmonary and cardiovascular diseases, current evidence supports
that asthma or COPD is not a contraindication for cardioselective ß-
blockers therapy. These patients should not be denied a therapy that
markedly reduces cardiovascular symptoms and mortality. Low dose
initiation and gradual up-titration of ß-blockers is currently recom-
mended. Thus, if indicated, cardioselective ß-blockers should be pre-
scribed in patients with asthma or COPD.
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